Lapatinib Impurity 6;746591-42-4
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Number: L079006
English Name: Lapatinib Impurity 6
English Alias: 5-(4-((4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-carbaldehyde
CAS Number: 746591-42-4
Molecular Formula: C₂₆H₁₈FN₃O₃
Molecular Weight: 439.44
Product Advantages: Lapatinib Impurity 6 has high purity and excellent chemical stability. Its structure is confirmed by precise analytical methods such as nuclear magnetic resonance and mass spectrometry, and it remains stable and uniform under different experimental conditions. As a reference substance, its precise purity control and stable physical-chemical properties ensure the accuracy and repeatability of Lapatinib impurity detection results, providing a reliable basis for pharmaceutical quality research and quality control.
Application Fields:
Quality Control: Used as an impurity reference standard for the development and validation of detection methods for Lapatinib bulk drugs and formulations, ensuring that the sensitivity and specificity of detection methods meet pharmaceutical quality standard requirements.
Process Optimization: Monitors the content of this impurity during drug production, and assists in optimizing the synthesis process by analyzing its formation pathway to reduce impurity generation and improve product quality.
Stability Studies: Analyzes the change trend of this impurity under different storage conditions in drug stability tests, providing data support for determining the shelf life and storage conditions of drugs.
Background Description: Lapatinib is a targeted drug for the treatment of HER2-positive breast cancer. In its research, development, production and quality control, impurity research is a key link to ensure drug safety and effectiveness. As a related impurity of Lapatinib, Lapatinib Impurity 6 may originate from side reactions or intermediate residues in the synthesis process. Excessive content may affect drug efficacy or bring safety risks. Therefore, the study of this impurity is an important part of the Lapatinib quality evaluation system.
Research Status: Currently, research on Lapatinib Impurity 6 mainly focuses on detection technology and impurity generation mechanisms. In terms of detection technology, advanced methods such as Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) have been developed to achieve trace detection. By simulating the synthesis reaction and storage environment, it is found that the formation of this impurity is related to the by-products of fluorobenzylation reaction. Optimizing the reaction solvent (such as replacing methanol with dimethyl sulfoxide) can reduce its generation. In addition, the study on the effect of this impurity on the efficacy and safety of Lapatinib is still being further explored.
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
